



Major Sponsors

 Bristol-Myers Squibb  
 PHARMACEUTICAL COMPANIES  
of Johnson & Johnson

Sponsors

    
 

Aula Magna  
Hospital Universitario Fundación  
Jiménez Díaz  
Grupo  quirónsalud

Inscripciones:  
[formacion.iisfjd@fjd.es](mailto:formacion.iisfjd@fjd.es)



Solicitada acreditación a la Comisión de  
Formación Continuada de las Profesiones  
Sanitarias – Sistema Nacional de Salud.

**iis**  
**FJD**  
INSTITUTO DE  
INVESTIGACIÓN  
SANITARIA  
FUNDACIÓN JIMÉNEZ DÍAZ

Lymphoma diagnosis and targeted treatment is challenged by the introduction of new drugs and refinements in the definition of new entities. This FJD Symposium will cover new markers and opportunities for a precision lymphoma medicine.

#### Clinical case discussion/Forum

Instructive lymphoma/leukemia cases presented by both clinicians and pathologists will be discussed along 5 different sessions, in total more than 6 hrs. In principle, 25 cases will be selected from submitted proposals.

Cases are expected to cover new areas of lymphoma/leukemia diagnosis and targeted treatment

**15:00-15:30:** M. Rodriguez Pinilla (FJD): Nanostring data in T-cell and B-cell lymphoma  
**15:30-17:15:** Clinical case discussion Forum

- Case 10.** A. António/R Córdoba (FJD): ALK+ Large B-Cell Lymphoma
- Case 11.** D. Cieza (FJD): CTCL/ALCL
- Case 12.** P. Beltran (HUIE): Gray zone lymphoma
- Case 13.** C. Santonja (FJD): Cutaneous lymphoma or autoimmune disorder?
- Case 14.** M. Mollejo (HVS, Toledo): Splenic lymphoma
- Case 15.** L. Prieto (FJD): Atypical presentation of a cutaneous T-cell lymphoma
- Case 15B.** J. Menarguez (HUGM): B-cell lymphoma treated with anti- CD79

## Provisional program

### Thursday, 18th October

**10:00-10:15:** F. Rojo/P. Llamas/C. Ayuso: Meeting introduction

**10:15-10:45:** Graham Collins (Oxford University Hospitals):

Immunotherapy for Non-Hodgkin's Lymphoma

**Case 1.** R. Córdoba (FJD): Primary mediastinal LBCL

**Case 2.** G. Salvatierra (FJD): Primary mediastinal LBCL

**Case 3.** M. Garcia Cossio (HRyC): Plasmablastic lymphoma

**Case 4.** M. Boiza (FJD): HHV8 lymphoproliferative disorders

**Case 5.** P. Henrique (FJD): Monoclonal gammopathy and lymphocytosis

**12:00-12:30:** Coffee break

**12:30-13:00:** JF. Piqueras/M Villa (CBM): Molecular basis of T cells lymphoblastic leukemia

#### 13:00-14:00: Clinical case discussion Forum

**Case 6.** SM. Rodriguez Pinilla (FJD): NK/T-cell lymphoma

**Case 7.** J. Forteza (Universidad Católica de Valencia), Hodgkin Lymphoma vs. Diffuse Large B-cell lymphoma

**Case 8.** F. Camacho (Hospital Universitario de Getafe): Progression in SMZL

**Case 9.** P. Dominguez (HURJC): EBV+ lymphoproliferative disorder

**14:00-15:00:** Lunch

### Friday, 19th October

**09:00-09:30:** M. Roemer (VU University Medical Center): Predicting Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

#### 09:30-11:00: Clinical case discussion Forum

**Case 16.** JF. García (MD Anderson Madrid): Hodgkin Lymphoma, therapy resistance

**Case 17.** C. Montalbán (MD Anderson Madrid): Hodgkin lymphoma

**Case 18.** T. Villaescusa (FJD): Hodgkin Lymphoma

**Case 19.** G. Salvatierra (HURJC): Angioimmunoblastic TCL

**Case 20.** R. Salgado (FJD): AITL/MDS/AML

**Case 21.** T. Arquero (FJD): T-Cell lymphoma

**11:00-11:30:** Coffee break

**11:30-12:00:** T. Eyre(Oxford University Hospitals): Mechanisms of resistance of BTKi in CLL and MCL

#### 12:00-13:00: Clinical case discussion Forum

**Case 22.** M. Sanchez-Beato (HUPH) : CLL progression

**Case 23.** G. Vega (FJD): Mantle Cell Lymphoma

**Case 24.** S. Martin (FJD): Mantle Cell lymphoma

**Case 25.** R. Salgado (FJD): Splenic lymphoma

**13:00-13:30:** E. Campo(H Clinic, Barcelona): CyclinD1-negative Mantle Cell Lymphoma

**13:30-14:00:** S. Barrans (Leeds Teaching Hospitals NHS Trust): Molecular profiling in the diagnosis of DLBCL